Cedar

A VP of Revenue Cycle or CFO at a mid-to-large health system or specialty physician group (ApolloMD, Talkiatry, Novant, Allegheny Health Network, Advanced Dermatology) whose patient collections have flatlined and whose statements are the worst-rated touchpoint in her entire patient experience survey. Cedar's navigation splits its buyers into two audiences (Health Systems & Hospitals and Clinician Services Providers), which is honest about who actually signs the contract. The problem is the hero does not sound like either of those humans when they describe their job at a board meeting.

Patient financial experience. The patient-facing slice of revenue cycle management. An existing shelf every health system CFO already shops on. Cedar sits alongside Waystar, R1 RCM, Experian Health, and a pack of newer point solutions (Collectly, Inbox Health, AccessOne). Cedar's category language has drifted three times in five years: "patient financial engagement" (2020), then "patient financial experience" (2023), and now "one intelligent platform that unifies billing, payments, coverage, and support" (2026). Each rename moved Cedar further from the specific thing the CFO is trying to fix and closer to generic platform consolidation language the whole category already uses.

Patient financial experience is now a late pragmatist category. The "patients hate medical bills" insight is not a reframe anymore, it is table stakes. Every RCM vendor, every EHR, and every payer has shipped a patient billing mobile experience by now. The buyer is no longer asking "should I upgrade my patient billing?" She is asking "which of the six vendors currently pitching me will actually move my collection rate without adding a second platform I have to pay for forever?"

Copy implication: This category cannot be sold with "patients deserve better" copy anymore. The remaining buyers are CFOs and revenue cycle VPs who need named references at their exact size, a published collection-rate delta, and proof that Cedar will not be the twelfth vendor they replace in five years.

The chain is intact. Cedar has the numbers, the named customers, and a genuinely differentiated capability (Cedar Cover) no competitor can currently match. The problem is that none of this specificity reaches the hero. The hero is three abstractions stacked in a row.

"Cedar collects the money other vendors wrote off, and the patients thank us for it."

Defensible, specific, and publicly backed by $30M in new net profit at Novant, 42% collection lift at ApolloMD, and a 96% patient satisfaction score at Crystal Run. This is the sentence a CFO would text to another CFO. It does not appear in Cedar's hero, subhead, or CTAs.

Founded 2016 in New York City by Florian Otto, M.D., Ph.D. (CEO, ex-Zocdoc commercial leadership, ex-Groupon Brazil) and Arel Lidow (ex-VP Product at AppNexus). The founder profile is unusually rare for healthcare billing. A clinician-operator paired with a consumer-marketplace product lead (the pairing you would design if you believed medical bills were a consumer experience problem disguised as a finance problem).

• Jun 2018: $36M Series B led by Kinnevik
• Jun 2020: $102M Series C led by Andreessen Horowitz (Kaiser Permanente, Thrive, Founders Fund participating)
• Mar 2021: $200M Series D led by Tiger Global at a $3.2B valuation (roughly $425M raised to date)
• May 2021: Acquires OODA Health for $425M, folding payer-provider billing into the platform (now Cedar Cover)
• 2026 cumulative metrics: 58M+ patients served, 1.3B payment interactions, $13.6B in patient payments processed
• Named customers (current site): Novant Health, Allegheny Health Network, Providence, TeamHealth, ApolloMD, NAPA, Talkiatry, Advanced Dermatology, Unio Health Partners, Allina Health, LCMC Health, USAP, Tend, Crystal Run, West Tennessee Healthcare, AnMed Health

1. The $3.2B March 2021 mark is five years stale. In a healthcare software market that has re-rated hard since 2022, a five-year-old Tiger Global valuation is pressure on every renewal and every new logo. The copy has to earn a premium that the cap table assumes.
2. The Epic MyChart billing default is the actual competitor. Every Epic health system already has a patient billing module they are paying for. Cedar wins when the CFO concludes MyChart is underperforming by enough to justify a second vendor. Nothing in the hero forces that conclusion.
3. The trophy-logo roster rotated. Yale New Haven, ChristianaCare, and Summit CityMD (the Series D press-release customers) are absent from the current case studies page. The new roster leans toward specialty physician groups and regional systems (ApolloMD, Talkiatry, AnMed, Unio, Crystal Run), which is a real book of business but also a different story than the Series D narrative implied.
4. Cedar Cover is the most differentiated capability and the most buried. A unified patient bill across payer and provider (the entire reason OODA cost $425M) is now listed as a sub-bullet under "Expand Coverage and Aid." The payer audience has been quietly demoted out of the "Who we serve" menu. The wedge is still in the product. It is not in the pitch.
5. The multi-product positioning trap. Cedar now has four product lines (Cedar Pay, Cedar Cover, Cedar Support, Kora AI) across two audience segments (Health Systems & Hospitals, Clinician Services Providers). The hero tries to position the company instead of any one product for any one buyer. The result is a headline that says nothing specific about any of them. A CFO evaluating Cedar Pay sees the same hero as a payer executive evaluating Cedar Cover, and neither walks away knowing what Cedar does for her specifically.
6. The nonconsumer is the largest revenue pool and the copy doesn't speak to her. Hundreds of community hospitals and physician groups still run paper statements plus an outsourced early-out vendor. They are not evaluating patient financial experience platforms. They do not consider themselves in this category at all. They are nonconsumers who have decided the switching cost of a new billing platform exceeds the ROI. Cedar's published numbers ($30M at Novant, 42% lift at ApolloMD) are exactly the evidence that could convert a nonconsumer, but the hero's "Built for patients. Powered by intelligence. Proven in performance." is category-insider language that the paper-statement CFO would never click on. The largest addressable segment is not the CFO already shopping Cedar vs. Waystar. It is the CFO who still thinks her paper statements and early-out vendor are good enough.

The hero is three sentences in a row that are each trying to be the headline. "Built for patients. Powered by intelligence. Proven in performance." A cold reader cannot tell which one is the real claim, so she picks none. Three-verb laundry lists are a tell that the writer could not pick the one that matters. Here it is three whole phrases.

The category cue is missing. "Unifies billing, payments, coverage, and support" describes the internal architecture of the platform, not the thing a VP of Revenue Cycle is trying to fix. She is not thinking "I need a platform that unifies four product modules." She is thinking "my patient collection rate is 34% and my statement NPS is negative."

The awareness stage is miscalibrated. The hero assumes a buyer who already believes patient financial experience is a category she should buy a dedicated platform for. Most Epic-shop CFOs are not at that stage yet. They are still asking whether MyChart billing is good enough. The hero has to answer that question, and it doesn't.

For the solution-aware CFO who already owns Epic MyChart billing and is asking whether a dedicated vendor is worth the second contract.

• Opens on the biggest number Cedar can publicly claim. $30M in 12 months at a named customer the CFO has heard of. A specific dollar figure attached to a specific brand is the fastest way to earn attention from a reader who has seen this pitch eleven times this year.
• Names the enemy in one phrase. "Replacing their patient statements" tells the CFO exactly which system she is replacing, and the system is usually Epic's default, which she already suspects is underperforming.
• The punch lands last. "By replacing their patient statements" closes the sentence where the idea weighs most, and makes the enemy the statement, not the vendor.
• Subhead stacks three proof points in descending specificity. ApolloMD 42%, Advanced Dermatology $9.5M, AHN/Highmark $17M. Each one is a real, dated, publicly cited number. No logo bar required.
• The AHN/Highmark line earns Cedar Cover its position back. The parenthetical (the only vendor that sits on both sides of the payer-provider seam) finally surfaces the most differentiated capability Cedar paid $425M to acquire.
• Two CTAs, both rewards. "See the collection lift for a system your size" promises a calculator. "Read the Novant case study" promises a peer story. Neither asks the CFO to pay in calendar time before she knows what she gets.
• Passes the swap test cold. Waystar, R1, and Collectly cannot drop their logo on this. Novant is Cedar's customer, the $30M is Cedar's number, and the payer-provider seam line describes only Cedar Cover.

For the CFO who still thinks the Epic MyChart billing module is fine. The hero has to reframe the decision she thinks she already made.

• Names the enemy the CFO didn't know she had. The Epic MyChart billing module she already owns. The reframe: it is not broken, it is just quietly leaving money on the floor. That is the sentence she has not heard before.
• Specificity converts. "34 cents on every patient dollar" is a claim the reader can argue with, which is exactly what makes it credible. Generic "poor collections" is not.
• The parenthetical does the risk-of-inaction work. Bad debt, write-offs, and a collections agency your patients will never forgive you for. Three consequences in one clause, stacked so the CFO feels the cost of doing nothing before she hears the pitch.
• 1.3 billion interactions is the only differentiator AI copy is allowed to claim in 2026. Not "AI-powered." The size of the training set. Cedar has the number. Most competitors don't.
• Ends on the $30M anchor. One sentence. One customer. One number. The reader remembers this and texts it to her CFO peer.
• Single CTA, promising a calculator. A CFO scanning a pitch wants a number for her own system, not a sales call. "See what 34 cents on the dollar costs a system your size" is the thing she was going to try to calculate anyway.

• Try to speak to patients. Patients are the end user, not the buyer. Both rewrites commit fully to the CFO and VP of Revenue Cycle.
• Lead with "AI" or "intelligent." AI is assumed infrastructure in 2026. The size of the training data set earns the claim.
• Use any wallpaper word. No "platform," "unify," "intelligent," "seamless," "transform," "empower," "comprehensive," or "end-to-end."
• Claim anything Cedar hasn't already published. Every number and every customer name is already on cedar.com or in a cited case study.
• Write prescriptive strategy. The rewrites demonstrate what the existing substance could sound like. They do not tell Cedar what to build next.

Cedar's category language has drifted three times in five years: "patient financial engagement" (2020), "patient financial experience" (2023), and now "one intelligent platform that unifies billing, payments, coverage, and support" (2026). Each rename moved further from what the CFO calls this problem in her own language. The buyer shops "patient billing" or "patient collections." She does not shop "unified intelligent platforms." The category cue on the homepage is vendor architecture language, not buyer language.

The real competitor is the Epic MyChart billing module, which every Epic shop already owns and has already integrated. The secondary competitor is paper statements plus an outsourced early-out vendor. Neither is named or confronted in the hero. The copy assumes a buyer who has already decided to buy a dedicated patient financial experience platform. Most buyers have not made that decision yet. They are still asking whether MyChart billing is good enough. The hero has to answer that question and it doesn't.

Cedar has two genuinely non-copyable attributes. First: Cedar Cover, the only payer-provider billing bridge in the category (acquired for $425M). No competitor can replicate this without their own payer acquisition. Second: 1.3 billion patient payment interactions training a billing-specific model, a corpus size no competitor has disclosed. Both are buried below the fold. Cedar Cover is a sub-bullet under a product page. The 1.3B number appears in small print. Neither reaches the hero or the first scroll.

The numbers are exceptional. Novant $30M net profit in 12 months. ApolloMD 42% collection rate lift. Advanced Dermatology $9.5M in one year. AHN/Highmark $17M in incremental patient payments via Cedar Cover. Crystal Run 96% patient satisfaction. All named, all published, all falsifiable. The hero says "Proven in performance" without including a single one. Every number lives in a case study carousel 800 pixels below the fold. The strongest proof in the entire patient financial experience category is invisible in the first viewport.

The navigation splits into two audiences (Health Systems & Hospitals, Clinician Services Providers). The hero speaks to neither specifically. "Built for patients" is addressed to the wrong person entirely (the patient is the end user, the CFO is the buyer). The actual beachhead — a VP of Revenue Cycle or CFO at a mid-to-large health system whose patient collections have flatlined — is never named in the copy. The hero serves everyone, which means it serves no one.

"Built for patients. Powered by intelligence. Proven in performance." is three statements, each of which could be the headline for a different company selling a different product. After four seconds a cold CFO cannot answer "what does this do for me?" or "how is this different from the MyChart billing I already have?" The brain is drawn toward clarity and away from confusion. This hero is three competing signals, not one clear one.

Cedar Pay (patient billing), Cedar Cover (payer-provider bridge), Cedar Support (patient communications), Kora AI (voice agent for billing calls), 1.3B-interaction training corpus, named customer references across health systems and physician groups. The whole product is real and publicly evidenced. The problem is that a late-pragmatist buyer needs to see the whole product stacked in one paragraph she can forward to her CFO, and instead it is distributed across four product pages and a case study carousel.

Physician-operator CEO (Florian Otto, M.D., Ph.D., ex-Zocdoc). Named customers including Novant, Providence, Allegheny Health Network, TeamHealth, ApolloMD. Published dollar-denominated outcomes at named institutions. a16z, Tiger Global, Kaiser Permanente as investors. The credibility inventory is deep. The only weakness is that the trust evidence is scattered across case study tiles, press releases, and the About page instead of being concentrated in the first viewport. The hero says "Proven in performance" without proving anything.

The value drivers are the things that make a CFO want Cedar: $30M net profit at Novant, 42% collection lift at ApolloMD, Cedar Cover's payer-provider bridge ($17M at AHN/Highmark), Kora AI eliminating billing call center costs. These create demand. The objection handlers are the things that prevent a deal from dying in procurement: HIPAA compliance, SOC 2 certification, data governance posture, EHR integration certification. They do not create demand. No CFO has ever said "I need to buy a patient billing platform because it's HIPAA-compliant." The current homepage treats both categories as a flat feature list. The value drivers should lead. The objection handlers should be easy to find so they clear the gate fast, but they should never be confused with the reason the CFO picks up the phone.

CFOs and VPs of Revenue Cycle say "our patient collection rate is 34%," "patients are calling us to ask why they owe this," "we wrote off $8M in patient balances last year," "our statement NPS is negative." Cedar's copy says "built for patients," "powered by intelligence," "unified platform." The mismatch between buyer voice and vendor voice is severe. The real sentences are already in Cedar's published case studies. The hero just doesn't use them. A late-pragmatist buyer who has already talked to Waystar and R1 this quarter will not slow down for "powered by intelligence." She will slow down for "$30M in net profit in 12 months at Novant." That is the sentence she was going to run herself.

Composite read: Cedar has the strongest dollar-denominated proof in the patient financial experience category. A $30M net-profit lift at Novant, a 42% collection rate lift at ApolloMD, a $17M payer-provider partnership at AHN/Highmark, and a $425M acquisition (OODA/Cedar Cover) that created the only payer-provider billing bridge in the market. The audit failure is not substance. It is that the hero — "Built for patients. Powered by intelligence. Proven in performance." — could belong to any company in any category and tells the CFO nothing.

The positioning flow: The competitive alternative is Epic MyChart billing (renewed by default inside every Epic shop) and paper statements plus outsourced early-out vendors. The unique attributes are Cedar Cover (the only payer-provider billing bridge) and a 1.3B-interaction billing-specific corpus no competitor has matched. The value those attributes enable is collection of money the Epic module leaves on the floor — quantified at $30M in 12 months at Novant. The customer who cares most is a VP of Revenue Cycle or CFO at a mid-to-large health system whose patient collection rate has flatlined. The market category is patient billing (the shelf the buyer already shops). The trend is the shift from "patients deserve better" advocacy to hard-dollar collection-rate accountability at the board level.

Value drivers vs. objection handlers: The value drivers are Novant's $30M, ApolloMD's 42%, Cedar Cover's payer-provider bridge, Kora AI's call-center cost elimination, and 1.3B patient payment interactions. These make the CFO want Cedar. The objection handlers are HIPAA compliance, SOC 2 certification, data governance, and EHR integration certification. These prevent the deal from stalling in procurement. Both are strong. The homepage treats them as a flat list instead of leading with value and clearing objections second.

The nonconsumption opportunity: The largest addressable segment is not the CFO evaluating Cedar vs. Waystar. It is the CFO at a community hospital or physician group who still runs paper statements and an outsourced early-out vendor and has decided the switching cost of a new platform exceeds the benefit. Cedar's published numbers are the exact evidence that could convert these nonconsumers (paper-statement systems that wrote off $30M at Novant's scale are writing off proportionally at every size). But the hero's category-insider language never reaches them. The copy that converts a nonconsumer has to start with the problem she already knows she has ("your collection rate is 34%"), not with the category she has not yet decided to shop.

• cedar.com · homepage hero verbatim, nav audience split, category language, CTAs, cumulative metrics (58M patients, 1.3B interactions, $13.6B processed)
• cedar.com/about-us · founding team, founding year, NYC HQ
• cedar.com/solutions/cedar-pay · /cedar-cover · /cedarsupport · /kora-ai · product taxonomy and Cedar Intelligence language
• cedar.com/resources/case-studies · current customer roster and published outcome numbers

• PR Newswire · March 2021 $200M Series D at $3.2B valuation led by Tiger Global announcement
• Crunchbase News · June 2020 $102M Series C led by Andreessen Horowitz coverage
• Modern Healthcare · June 2018 $36M Series B led by Kinnevik coverage
• Crunchbase · Cedar company profile, total funding, investor list

• Fierce Healthcare · "Medical billing startup Cedar to acquire Ooda Health for $425M" (May 2021)
• Fierce Healthcare · "Cedar scores $102M Series C and new partnership with Novant Health" (June 2020)
• Healthcare Dive · "Cedar to acquire Ooda Health for $425M, moving into insurance market" (May 2021)
• MedCity News · "Cedar snags $200M in new funds, boosting valuation to $3.2B" (March 2021)
• Payments Dive · Cedar-OODA acquisition coverage and strategic rationale (2021)

• cedar.com/case-studies/novant-health-adds-30m-in-net-profit-in-12-months-with-cedar-pay · Novant $30M net profit in 12 months
• cedar.com case studies · ApolloMD 42% collection rate lift, Advanced Dermatology $9.5M in one year, AnMed 24% collections lift, West Tennessee 41% payment lift, Talkiatry 96% online payments, Crystal Run 96% patient satisfaction
• Allegheny Health Network + Highmark case study · $17M incremental patient payments via Cedar Cover
• Cedar homepage logo bar · Novant, Providence, Allegheny Health Network, TeamHealth, ApolloMD, NAPA, Talkiatry, Advanced Dermatology, Unio Health Partners, Allina Health, LCMC, USAP, Tend

• waystar.com · public RCM suite including patient financial experience module
• r1rcm.com · end-to-end outsourced revenue cycle
• experianhealth.com · patient billing and estimates
• collectly.com, inboxhealth.com, accessone.com · point-solution patient billing challengers
• Epic · MyChart billing module (the status quo competitor in every Epic shop)
• CB Insights · Cedar alternatives and peer set tagging

• cedar.com/blog · Florian Otto founder profile (ex-Zocdoc, ex-Groupon Brazil, ex-McKinsey, M.D. Ph.D.)
• LinkedIn · Arel Lidow (ex-VP Product, AppNexus)